Literature DB >> 15627939

Bone mineral density in a paediatric spinal muscular atrophy population.

M Kinali1, L M Banks, E Mercuri, A Y Manzur, F Muntoni.   

Abstract

BACKGROUND/
OBJECTIVE: Reduced bone mineral density is a feature of patients with reduced mobility. The aim of this study was to assess bone mineral density in children with spinal muscular atrophy (SMA) and to evaluate bone mineral density in relation to age and motor disability. PATIENTS AND METHODS: We analysed bone mineral density measurements on twelve patients (4 with SMA type II, mean age 8.2 years [range 6.2 - 11.8]; 8 with SMA type III, mean age 11.8 years [range 5.5 - 20]). Dual-energy X-ray absorptiometry (DXA) was used to determine total body bone mineral density. The results were matched with published normative data for age and sex for a white Caucasian population.
RESULTS: The total body bone mineral density values were in the normal range in 10 out of the 12 SMA patients studied, all below the age of 17 (mean age 8.8 years [range 5.5 - 16.33]). Four of them had SMA II and six had had SMA III and were still ambulant. Total body bone mineral density was, however, below 2 SD in the remaining 2 patients aged 19.7 and 20 years, respectively. Both had SMA III but had lost independent ambulation for a period of 3.5 years.
CONCLUSION: Our results suggest that bone mineral density was surprisingly normal in most of the young SMA children studied. This is in contrast to what is reported in other conditions characterised by reduced mobility such as Duchenne muscular dystrophy. However, there was a tendency to decreasing bone mineral density with increasing age, not always related to the ability to walk, with the two eldest patients having the lowest values in spite of a relatively good mobility. These findings suggest that factors other than mobility are likely to have an effect on SMA bone mineral density.

Entities:  

Mesh:

Year:  2004        PMID: 15627939     DOI: 10.1055/s-2004-830366

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  13 in total

1.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

Review 2.  Spinal Muscular Atrophy.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 3.  Spinal muscular atrophy: diagnosis and management in a new therapeutic era.

Authors:  W David Arnold; Darine Kassar; John T Kissel
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

Review 4.  Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling.

Authors:  Srinivasan Shanmugarajan; Kathryn J Swoboda; Susan T Iannaccone; William L Ries; Bernard L Maria; Sakamuri V Reddy
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

5.  Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy.

Authors:  Srinivasan Shanmugarajan; Eichi Tsuruga; Kathryn J Swoboda; Bernard L Maria; William L Ries; Sakamuri V Reddy
Journal:  J Pathol       Date:  2009-09       Impact factor: 7.996

6.  Intravenous bisphosphonate therapy in children with spinal muscular atrophy.

Authors:  N Nasomyont; L N Hornung; H Wasserman
Journal:  Osteoporos Int       Date:  2019-12-02       Impact factor: 4.507

7.  Fractures in children with Pompe disease: a potential long-term complication.

Authors:  Laura E Case; Rabi Hanna; Donald P Frush; Vidya Krishnamurthy; Stephanie DeArmey; Joanne Mackey; Anne Boney; Claire Morgan; Deyanira Corzo; Susan Bouchard; Thomas J Weber; Yuan-Tsong Chen; Priya S Kishnani
Journal:  Pediatr Radiol       Date:  2007-03-07

Review 8.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

Review 9.  Biomarkers in rare disorders: the experience with spinal muscular atrophy.

Authors:  Francesco D Tiziano; Giovanni Neri; Christina Brahe
Journal:  Int J Mol Sci       Date:  2010-12-24       Impact factor: 5.923

Review 10.  Spinal muscular atrophy.

Authors:  Adele D'Amico; Eugenio Mercuri; Francesco D Tiziano; Enrico Bertini
Journal:  Orphanet J Rare Dis       Date:  2011-11-02       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.